2025 · Poster Presentation · Pharma Partner · Hepatology
25
Total Publications
8
Abstract/Manuscript
1
Oral Presentation
16
Poster Presentation
2025 · Abstract/Manuscript · Yes
The Magnitude of Polypharmacy and Role of Disease Severity and Patient Sex in Medication Use Among Patients With MASLD Enrolled in TARGET-NASH.
Read more →2025 · Abstract/Manuscript · Yes
DAA-PASS: A Prospective Evaluation of HCC Recurrence After Direct Acting Antiviral Therapy.
Read more →2025 · Poster Presentation · Pharma Partner · Hepatology
Relationship between non-invasive tests, clinical outcomes and liver biopsy among people with MASH under real-world conditions.
Read more →2024 · Poster Presentation · Pharma Partner · Hepatology
Time to Disease Progression and All-Cause Mortality in Adult MASH Patients in Real-World US Cohort.
Read more →2024 · Poster Presentation · Pharma Partner · Hepatology
Characteristics of adult MASH patients and factors associated with MASH-relevant clinical endpoints in a real-world US cohort.
Read more →2024 · Poster Presentation · Pharma Partner · Hepatology
Understanding Metabolic Dysfunction-Associated Steatohepatitis: Differences in Clinical and Demographic Characteristics Across Racial and Ethnic Groups.
Read more →2024 · Poster Presentation · University of Birmingham (UK) · Hepatology
Real-World Use of Glucagon-Like Peptide 1 Receptor Agonists in Patients with MASLD: A Cross-Sectional Analysis from TARGET-NASH.
Read more →2024 · Poster Presentation · University of Birmingham (UK) · Hepatology
A prospective assessment of disease progression impact on patient-reported outcomes in metabolic dysfunction-associated steatotic liver disease.
Read more →2024 · Poster Presentation · Pharma Partner · Hepatology
Non-invasive tests as a prediction tool to assess MASH resolution score.
Read more →2024 · Poster Presentation · Derek Gazis · Hepatology
A longitudinal assessment of cardiovascular risk for NASH/MASH patients enrolled in TARGET-NASH.
Read more →2024 · Abstract/Manuscript · Duke
Concordance of MASLD and NAFLD nomenclature in youth participating in the TARGET-NASH real-world cohort.
Read more →2024 · Abstract/Manuscript · Yes
High Concordance Between Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease in the TARGET-NASH Real-World Cohort.
Read more →2024 · Poster Presentation · Pharma Partner · Hepatology
Relationship between liver biopsy fibrosis stage and clinical outcomes among persons with MASLD/MASH.
Read more →2023 · Poster Presentation · Derek Gazis · Gastroenterology
Outcomes of early vs. delayed advanced therapy among patients with moderate ulcerative colitis in the United States: TARGET-IBD.
Read more →2023 · Poster Presentation · Derek Gazis · Gastroenterology
Treatment Journey among patients with moderate ulcerative colitis in the United States: TARGET-IBD.
Read more →2023 · Abstract/Manuscript · Pharma Partner
Impact of itch on quality of life in people with primary biliary cholangitis: a plain language summary.
Read more →2023 · Oral Presentation · Derek Gazis · Hepatology
Non-alcoholic Steatohepatitis Disease Progression in Participants from the United States TARGET-NASH Real World Longitudinal Observational Study.
Read more →2022 · Poster Presentation · Yes · Hepatology
The Role of Disease Severity and Gender in Polypharmacy Among Patients with NAFLD Enrolled in TARGET-NASH.
Read more →2022 · Poster Presentation · Pharma Partner · Gastroenterology
Treatment patterns among moderate-to-severe ulcerative colitis patients in TARGET-IBD.
Read more →2022 · Poster Presentation · Yes · Methods/Pharmacoepi
Healthcare Utilization and Charges Associated with US Hospitalized Adult Patients with COVID 19.
Read more →2022 · Abstract/Manuscript · Emory
Variation in Alanine Aminotransferase in Children with Non-Alcoholic Fatty Liver Disease.
Read more →2022 · Abstract/Manuscript · Pharma Partner
Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis.
Read more →2021 · Abstract/Manuscript · Yes
Factors Associated with Readmission in the US Following Hospitalization with COVID-19.
Read more →2019 · Poster Presentation · Yes · Methods/Pharmacoepi